M&A Trends: What Will Reshape Deals in 2026?

The M&A market in 2026 is a strange beast. On one hand, you’ve got constant market volatility. On the other, deal-making has been incredibly resilient. Companies aren’t just hunkering down. Many are using M&A to aggressively reposition themselves for growth. The real question is what trends are actually driving deals in this environment and how you should be preparing your firm to act.

The Shifting Sands of Valuation: Beyond Traditional Multiples

In past cycles, valuations were pretty straightforward, mostly leaning on historical earnings multiples or standard discounted cash flow models. Those are still the building blocks, but today’s market requires a lot more judgment. We’re seeing a major shift toward valuing a company’s future potential and its strategic fit, often way above its past performance. Just look at the explosion in AI and quantum computing. A company with some early-stage, but truly disruptive, AI intellectual property can get a premium that makes its current revenue look tiny. This is about the raw ability to reshape a market or open up entirely new lines of business.

A Reuters report from Q4 2025 backs this up, noting that enterprise software deals frequently hit valuations over 15x forward EBITDA if the firm could show a believable plan for AI integration or had unique proprietary data. That’s a world away from the 8x to 10x multiples we saw for similar companies just three years ago. Buyers are now paying for what a target can become, not just what it is today. For sellers, this means strong financials aren’t enough. You have to be able to sell the story of innovation and where you’ll be in the market five years from now, supported by a credible tech roadmap.

The Rise of “Non-Financial” Due Diligence

Due diligence has moved way beyond the balance sheet. Environmental, Social, and Governance (ESG) factors are now front and center in deal evaluation. Big institutional investors, especially, are digging into a target’s carbon footprint, its labor practices, and its governance with a fine-toothed comb. A recent AP News analysis showed several deals that were repriced or just fell apart because of poor ESG scores. This is about assessing long-term risk and protecting the brand. A company with a bad environmental track record isn’t just risking fines. It’s risking a consumer backlash and an inability to hire good people, both of which will kill shareholder value after the acquisition.

And cybersecurity due diligence is now a deal-breaker. Period. With cyber threats getting more sophisticated every day, you’re taking on massive risk if your target’s digital house isn’t in order. I’ve personally seen deals get stuck in limbo for months, and sometimes die completely, after a security audit found critical holes or, even worse, an undisclosed breach. The cost to fix a major cyber incident after you’ve closed can easily be more than the purchase price itself, which makes a thorough pre-deal audit essential. We’re talking detailed penetration testing, vulnerability scans, and deep dives into data governance policies that go far beyond the checklists of five years ago.

Strategic Divestitures and Portfolio Optimization

In this kind of market, companies have to show a clear path to profit. That often means getting rid of non-core assets that are a distraction or a drain on the bottom line. We’re seeing a big uptick in these strategic divestitures, with corporations actively cleaning up their portfolios to focus on what they do best. It’s a deliberate strategy to unlock value and simplify the business. For instance, a global conglomerate might sell its logistics division, which has been struggling, to pour that cash back into its fast-growing software arm, boosting its overall margins and how the market sees it.

Private equity firms are the natural buyers here. They’re specialists at wringing out performance in specific industries, making them a perfect fit for a business unit that might have been ignored or underfunded inside a giant corporation. The seller gets capital and can refocus, and the PE buyer gets a potentially undervalued asset that has a lot of room for improvement with the right operational focus. The trick for sellers is to build a convincing case for the divested unit’s future as a standalone business, even if it didn’t fit the parent company’s strategy.

The SPAC boom from a couple of years back has also created a whole new group of potential divestiture targets. A lot of those companies that went public via SPACs are now under immense pressure to hit growth targets they probably shouldn’t have promised. When they miss, or when the market turns on them, they start looking to sell off divisions or even go private again to get out from under the public microscope. This just adds another layer of opportunity and complexity to the divestiture market.

Technology and Healthcare: Enduring Hotbeds for M&A

Even with all the economic uncertainty, tech and healthcare are still driving a huge amount of M&A activity. These sectors are being changed by deep, long-term trends that don’t really care about short-term market jitters. In tech, the constant race for innovation in AI, cloud, and cybersecurity is what fuels consolidation. Big players are snapping up smaller, nimbler startups to get their hands on new tech, talent, and market access. A major cloud provider might buy a small AI firm that’s great at natural language processing to bolt that capability onto its enterprise platform. It’s pure capability acquisition.

Healthcare is a different story, driven by aging populations, biotech breakthroughs, and the push for more efficient, integrated care. As chronic diseases become more common, the demand for new drugs, better medical devices, and smarter delivery models just keeps growing. Big pharma companies are constantly on the hunt for biotech firms with promising drugs in the pipeline, and hospital systems are buying up clinics and tech companies to build out their patient services. We’re also seeing a ton of investment in digital health, especially in telehealth, remote patient monitoring, and AI-powered diagnostics. The whole healthcare market is fragmented, and with regulatory pressure increasing, consolidation is the logical way to gain efficiency and scale.

But while these sectors are hot, the deals themselves are getting more complicated. In tech acquisitions, buyers are doing much more rigorous technical due diligence, often bringing in third parties to review source code and check the architectural soundness of a platform. In healthcare, it’s all about regulatory compliance, IP protection, and validating clinical trial data. If you get any of that wrong, the deal can fall apart or leave you with huge liabilities down the road. You absolutely have to invest in pre-deal prep, especially when it comes to proving you have a strong IP portfolio and a clear path through the regulatory maze.

Cross-Border Deals: Working through Geopolitical Headwinds

Geopolitical friction is making things harder, but cross-border M&A isn’t stopping, it’s still a core part of any global growth strategy. Sure, some sectors and regions are under a microscope (especially anything involving tech transfers to certain countries), but the desire to expand internationally through acquisition is still there. Companies need access to new markets, different talent pools, and better supply chains, and often the only way to get them is through a cross-border deal.

Emerging markets, especially in Southeast Asia and parts of Latin America, are looking more and more attractive. They have growing consumer populations, lower operating costs, and aren’t as crowded with competitors as North America or Europe. A European consumer goods company, for example, might buy a local brand in Vietnam to get immediate market share and distribution, which is way faster than building from scratch. But doing these deals means you need a rock-solid understanding of local laws, culture, and the political climate. Diligence has to go beyond the financials to include geopolitical risk analysis, currency hedging strategies, and a careful plan for working through foreign investment reviews.

The increased scrutiny from national security bodies, particularly for deals in critical infrastructure and tech, means you have to plan for long regulatory delays and potential restrictions from governments. You have to bring in legal and regulatory advisors from day one. Trying to sidestep these issues is how deals die. I’ve seen several strategically sound deals get bogged down or blocked outright because the team didn’t pay enough attention to the national foreign investment review process. A good deal on paper can fall apart fast if you misread the geopolitical tea leaves.